Contact
Please use this form to send email to PR contact of this press release:
BeyondSpring’s Lead Asset, Plinabulin, Shows Superior Efficacy Compared to Neulasta for Prevention of Thrombocytopenia Induced by Docetaxel in Phase 2 Trial
TO: